Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Evolving quality oversight to limit sponsor burden
ICON implemented a Data Management Asset Lead (DMAL) role to provide oversight and ensure adherence to standards for a sponsor with limited bandwidth.
Patient cardiac safety
A digital health lead at a large pharmaceutical company came to ICON Outcome Measures to find a wearable that could capture continuous cardiac rhythms and be used to detect QT prolongation.
Applying statistical and programming expertise to overcome FDA challenges
ICON supported a biotech company in preparing for FDA submission by quickly mobilising a team to address unexpected comments on statistical analysis and data collection, resulting in timely BLA submission, enhanced data quality, and alignment with FDA requirements.
The importance of CRF design in cell and gene therapy studies
ICON partnered with a biotech sponsor to optimise Case Report Forms (CRFs) for an oncology cell and gene therapy trial. By adopting iRECIST criteria and standardising CRF templates, we reduced data duplication, ensured accuracy, and provided flexibility for subject re-treatment.
Improving early phase oncology clinical trial design
This case study explores two Bayesian model-assisted designs in the context of early phase oncology clinical trials, focusing on their application and impact on study design. It includes a review of each design’s operating characteristics, proposed amendments, and simulations.
Language Services: Voiceover and video localisation
ICON provided a fully localised and tested informational solution for patients that was consistent across platform components for online materials developed to train patients on the consent process.
Launching into an established market
ICON Market Access played a key role in informing a client’s go-to-market strategy, including analytics around market sizing, a competitive landscape assessment and a benefit design analysis for a long-acting, injectable anti-psychotic drug.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=niV-MiYV "Oncology care in commercial positioning"){kind=icon}
Chronic Myeloid Leukaemia
As a result of the multifaceted communication approach with sites and a strong partnership between ICON and sponsor, the study met its protocol-specified enrolment goal just 9 days beyond contracted Last Patient In date (LPI).
Electronic implementation and digital app localisation
ICON delivered a multifaceted omnichannel awareness campaign to provide a seamless customer experience between print and digital channels for a drug to treat PPD.
Driving payer education and awareness
ICON delivered a multifaceted omnichannel awareness campaign to provide a seamless customer experience between print and digital channels for a drug to treat PPD.
Rapid manuscript development and delivery
Through close collaboration with a client, the ICON team provided the support necessary to advance a critical COVID-19 manuscript from outline through submission to acceptance in only 20 days.
PKU-specific HRQol Questionnaire Development & Validation
ICON developed the first PKU-specific Quality of Life questionnaire available and validated in four age groups and seven languages.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.